Changes in Beneficial Ownership · 4
Organon & Co.
OGNNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1786554094.xml
Filing details
- Report period
- 2026-08-11
- Issuer
- Organon & Co.
- Issuer CIK
- 0001821825
- Trading symbol
- OGN
Reporting owner 1
- Name
- Arjona Ferreira Juan Camilo
- Reporting owner CIK
- 0001714080
- Relationship
- Officer
- Officer title
- Head of R&D & CMO
- Address
- C/O ORGANON &CO., 30 HUDSON STREET, FLOOR 33, JERSEY CITY, NJ, 07302
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-11 | M · Form 4 | 11,519 | A | 0 | 41,566.477 | D |
| Common Stock | 2026-08-11 | F · Form 4 | 4,134 | D | 13.62 | 37,432.477 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-08-11 | M · Form 4 | 11,519 | A | 0 | [F2] | [F2] | Common Stock | 11,519 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.↩ 1
Signature 1
- Signed
- /s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira
- Date
- 2026-08-12
Company context
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.